ALK and non-small cell lung carcinoma: This boost to the immune system's recognition had benefit for the survival of ALK+ NSCLC mice treated with the ALK inhibitor lorlatinib, and the addition of an anti‐CTLA4 ICI cured most of the mice treated (Fig. 1).